{"entity":{"id":"ascendo-biotechnology","kind":"company","name":"Ascendo Biotechnology","aka":["Ascendo Biotechnology Inc.","先知生物科技"],"tldr":"Ascendo Biotechnology makes an antibody that releases a brake on the body's first-line immune cells, aiming to help the immune system attack solid tumours that resist current immunotherapy.","summary":"Ascendo Biotechnology Inc., headquartered in Taipei, was founded in 2019 as a spin-out from BRIM Biotechnology, according to the company, by Dr Yen-Ta Lu of MacKay Memorial Hospital. It targets the TLT-1/CD11b innate immune checkpoint axis. ASD141, a first-in-class anti-CD11b monoclonal antibody that blocks TLT-1 signalling, is in a first-in-human phase 1 trial in advanced solid tumours (NCT06235437); ASD001, a CD11b-activating antibody for autoimmune disease, is preclinical. In May 2026 it completed an oversubscribed Series A with investors including Taiwania Capital (TaiAx Life Science Fund), Yuanta Venture Capital and Industrial Technology Investment Corporation. Its first registered cancer trial, NCT06235437, was posted on ClinicalTrials.gov in February 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.ascendobiotech.com/"},{"label":"Series A release, May 2026","url":"https://www.ascendobiotech.com/2026/05/08/ascendo-biotechnology-completes-oversubscribed-series-a-financing-to-advance-innate-immune-checkpoint-pipeline/"},{"label":"ClinicalTrials.gov: phase 1 trial of ASD141 (NCT06235437)","url":"https://clinicaltrials.gov/study/NCT06235437"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["monoclonal-antibody","checkpoint-inhibitor"],"targets":["cd11b"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year, spin-out origin and Taipei address from the company's About and Contact pages, read on 29 October 2026. The Series A release does not state an amount. None of the named investors has an OnCo investor record."],"hq":"Taipei","country":"TW","companyType":"biotech","website":"https://www.ascendobiotech.com/","founded":2019,"stage":"startup","investors":[],"funding":[{"round":"Series A","year":2026,"source":"https://www.ascendobiotech.com/2026/05/08/ascendo-biotechnology-completes-oversubscribed-series-a-financing-to-advance-innate-immune-checkpoint-pipeline/","note":"Oversubscribed; amount not stated in the release"}]},"route":"/companies/ascendo-biotechnology/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"target":[{"id":"cd11b","kind":"target","name":"CD11b","route":"/targets/cd11b/"}]}}